Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.63 |
| ▸ | PTK2 | Q05397 | 4/20 | 0.60 |
| ▸ | JAK2 | O60674 | 1/20 | 0.59 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.59 |
| ▸ | TYK2 | P29597 | 1/20 | 0.59 |
| ▸ | KDR | P35968 | 1/20 | 0.59 |
| ▸ | JAK3 | P52333 | 1/20 | 0.59 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.59 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.59 |
| ▸ | NTRK2 | Q16620 | 1/20 | 0.59 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.58 |
| ▸ | INSR | P06213 | 2/20 | 0.58 |
| ▸ | IGF1R | P08069 | 2/20 | 0.58 |
| ▸ | LRRK2 | Q5S007 | 10/20 | 0.58 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28969633 | 0.92 | MAP4K1 (0.54) | MAP4K1PTK2JAK2NTRK1TYK2 | |
| SCHEMBL30002296 | 0.92 | MAP4K1 (0.54) | MAP4K1PTK2JAK2NTRK1TYK2 | |
| SCHEMBL30002125 | 0.92 | MAP4K1 (0.62) | MAP4K1PTK2JAK2NTRK1TYK2 | |
| SCHEMBL24752673 | 0.92 | MAP4K1 (0.62) | MAP4K1PTK2JAK2NTRK1TYK2 | |
| SCHEMBL30001806 | 0.92 | LRRK2 (0.54) | MAP4K1PTK2JAK2NTRK1TYK2 | |
| SCHEMBL28969572 | 0.92 | LRRK2 (0.54) | MAP4K1PTK2JAK2NTRK1TYK2 | |
| SCHEMBL28969650 | 0.92 | LRRK2 (0.54) | MAP4K1PTK2JAK2NTRK1TYK2 | |
| SCHEMBL30002231 | 0.92 | LRRK2 (0.54) | MAP4K1PTK2JAK2NTRK1TYK2 | |
| SCHEMBL24752748 | 0.92 | MAPK3 (0.65) | MAP4K1PTK2JAK2NTRK1TYK2 | |
| SCHEMBL30001807 | 0.92 | MAPK3 (0.65) | MAP4K1PTK2JAK2NTRK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127800-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVE AND MEDICINAL USE THEREOF | SIGNET THERAPEUTICS INC. (CN) | 2025-04-24 | — | — | US | disclosed |
| EP-4450493-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVE AND MEDICINAL USE THEREOF | Signet Therapeutics Inc. (CN) | 2024-10-23 | — | — | EP | disclosed |
| CN-116870016-B | Heteroaromatic compound and medical application thereof | 希格生科（深圳）有限公司 | 2024-05-28 | — | — | CN | disclosed |
| CN-117412981-A | Phosphine oxide derivative and preparation method and application thereof | 希格生科（深圳）有限公司 | 2024-01-16 | — | — | CN | disclosed |
| CN-117043151-A | Pyrimidine or pyridine derivative and medical application thereof | 希格生科（深圳）有限公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-116870016-A | Heteroaromatic compound and medical application thereof | 希格生科（深圳）有限公司 | 2023-10-13 | — | — | CN | disclosed |
| WO-2023109751-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVE AND MEDICINAL USE THEREOF | 希格生科（深圳）有限公司 | 2023-06-22 | — | — | WO | disclosed |
| CN-115785154-A | Heteroaromatic ring compounds and medical use thereof | 希格生科（深圳）有限公司 | 2023-03-14 | — | — | CN | disclosed |
| WO-2022253081-A1 | PHOSPHINE OXIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 希格生科（深圳）有限公司 | 2022-12-08 | — | — | WO | disclosed |
| WO-2022253081-A1 | PHOSPHINE OXIDE DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 希格生科（深圳）有限公司 | 2022-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127800-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVE AND MEDICINAL USE THEREOF | PTK2, PDGFRB, PTK2B | MAP4K1 110/4885PTK2 1/4885JAK2 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.